IDO1 and cancer: However, the immunogenic effect of PTX is severely suppressed inside tumors, particularly by indoleamine 2,3‐dioxygenase (IDO)‐mediated immunosuppressiveness,[7] which lowers down the immune‐chemotherapeutic effect of PTX.[8] IDO is a negative feedback enzyme overexpressed in some cancer cells.